



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 374 899 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)
INID code(s) 30

(51) Int Cl.7: **A61K 45/00**, A61K 31/5575,
A61P 43/00, A61P 25/00,
A61P 25/22

(48) Corrigendum issued on:
10.03.2004 Bulletin 2004/11

(86) International application number:
PCT/JP2002/002513

(43) Date of publication:
02.01.2004 Bulletin 2004/01

(87) International publication number:
WO 2002/076505 (03.10.2002 Gazette 2002/40)

(21) Application number: **02705269.5**

(22) Date of filing: **15.03.2002**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **16.03.2001 JP 2001075398**

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
Osaka-shi, Osaka 541-8526 (JP)

(72) Inventors:
• **NARUMIYA, Shuh**
Kyoto-shi, Kyoto 606-0007 (JP)
• **MARUYAMA, Takayuki,**
Ono Pharmaceutical Co., Ltd.
Mishima-gun, Osaka 618-8585 (JP)

(74) Representative: **Henkel, Feiler, Hänzel**
Möhlstrasse 37
81675 München (DE)

(54) **REMEDIES FOR POST-TRAUMATIC STRESS DISORDER**

(57) The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds (EP₁ agonists), which activate EP₁ receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP₁ agonists such as (13E)-(11 α , 15S, 17S)-

2, 5-ethano-6, 9-dioxo-11, 15-dihydro-17, 20-dimethyl-prosta-13-enoic acid, PGE₁, or PGE₂, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).

EP 1 374 899 A8